OBJECTIVE: To investigate whether inhibition of Akt phosphorylation by the phosphatidylinositol 3-kinase (PI3K) inhibitor, wortmannin, reduces metastasis and angiogenesis in a human breast cancer cell line via nuclear factor (NF)-kBdependent matrix metalloproteinase (MMP)-9 and interleukin (IL)-8 pathways. METHODS: MDA-MB-231 cells were treated with wortmannin 0 -200 nM for 4 h. Restoration of Akt activity was evaluated by transfection of cells with constitutively active myristoylated Akt (myr-Akt). NF-kB, MMP-9 and IL-8 proteins were detected by electrophoretic mobility shift assay, Western blot or enzyme-linked immunosorbent assay. The chicken embryo chorio-allantoic membrane assay, cell motility and migration assays were used to evaluate angiogenesis and invasion in vitro. A mouse pseudo metastatic breast cancer model was used to assess the effects of wortmannin on metastasis and angiogenesis in vivo. RESULTS: Wortmannin inhibited the phosphorylation of Akt, upregulation of NF-kB, MMP-9, IL-8, and in vitro cell invasion and angiogenesis, in a dose-dependent manner. Transfection of myr-Akt reversed the cellular and biochemical effects of wortmannin in vitro. Wortmannin also significantly inhibited tumour metastasis and angiogenesis in vivo. CONCLUSION: The findings of the present study suggest that wortmannin inhibits metastasis and angiogenesis in breast cancer cells via PI3K/Akt/NF-kBmediated MMP-9 and IL-8 signalling pathways.
Introduction
The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signalling pathway plays an essential role in several cellular processes including proliferation, growth, survival, motility and angiogenesis; inhibition of this pathway has been shown to prevent metastasis of invasive cancers. 1 -3 Activation J Li, F Li, H Wang et al. Effects of wortmannin in human breast cancer cells (i.e. phosphorylation) of Akt is required for several events in the process of metastasis, including: migration of cells from the tumour environment into (and then out of) the circulation; proliferation; inhibition of apoptosis; angiogenesis. A series of steps leading to metastasis can be initiated by activation of Akt and research is ongoing to understand this further. 4 It has been suggested that Akt/nuclear factor (NF)-κB signalling may regulate cancer cell metastasis. 5, 6 Nuclear factor κB transcription factors regulate the expression of over 100 genes, depending on the various functional forms of NF-κB, the stimulus for activation and the cell type examined. Several reports have suggested that constitutively active NF-κB is associated with metastasis and angiogenesis of breast cancer cells. 7 -9 Tumour angiogenesis (which is necessary for breast cancer growth, invasion and metastasis) is also regulated by proangiogenic factors such as matrix metalloproteinase (MMP)-9 and interleukin (IL)-8, 10 -13 which are themselves regulated by NF-κB in breast cancer. 14 -16 Wortmannin is a fungal metabolite with high specificity for PI3K, causing 95% inhibition at concentrations of 100 nM; this closely correlates with the wortmannin concentrations required to induce apoptosis of growth factor-maintained cells. 17 The present study investigated the hypothesis that wortmannin can suppress metastasis and angiogenesis in a human breast cancer cell line (MDA-MB-231), both in vivo and in vitro, via inhibition of Akt activation and suppression of NF-κBregulated MMP-9 and IL-8 pathways.
Materials and methods

CELL CULTURE
A human breast cancer cell line (MDA-MB-231) was obtained from the American Type Culture Collection (Manassas, VA, USA) and was maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) without antibiotics, in a humidified atmosphere at 37°C with 5% carbon dioxide.
DRUG TREATMENTS AND CELL TRANSFECTION
The MDA-MB-231 cells were divided into three groups (1 × 10 6 cells per treatment condition) and treated with: (i) wortmannin (Sigma-Aldrich, St Louis, MO, USA) at concentrations of 0 -400 nM for 4 h; (ii) wortmannin 400 nM for 0 -4 h (0 -240 min); and (iii) wortmannin 400 nM for 4 h.
For the transfection experiments, a commercially available plasmid containing an active form of Akt, myristoylated (myr)-Akt (BioVector, Beijing, China), was purified using the Qiagen Plasmid Maxi Kit (Qiagen, Valencia, CA, USA). Following treatment with wortmannin 400 nM for 4 h, cells (approximately 1 × 10 6 ) were incubated with 1 µg of the myr-Akt plasmid and 5 µl of Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions, for 48 h in serum-deprived medium, to produce transiently transfected clones. There was no empty vector control.
PREPARATION OF NUCLEAR AND CYTOPLASMIC EXTRACTS
Following treatment with wortmannin as detailed above, soluble nuclear and cytoplasmic extracts were prepared from MDA-MB-231 cells from the three treatment groups, as described previously. 18, 19 Cytoplasmic extracts were obtained by diluting (1:200 dilution) the supernatant obtained after the first centrifugation (at 25 000 g for 20 min at 4°C) with 30 volumes of 20 mM 4-[2-hydroxyethyl]-1-piperazineethanesulphonic acid buffer (pH 7.9), 20% J Li, F Li, H Wang et al.
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(v/v) glycerol, 0.1 M potassium chloride, 0.2 mM ethylenediaminetetra-acetic acid (EDTA), 0.5 mM phenylmethylsulphonyl fluoride and 0.5 mM dithiothreitol. 19 Nuclear extracts, obtained according to previously reported methods, 18, 19 were stored in liquid nitrogen at -80°C; cytoplasmic extracts were stored at -20°C before use.
WESTERN BLOT
Protein levels of NF-κB p65, MMP-9 and IL-8 from xenograft tissues or cultured cells were analysed by Western blot. Cytoplasmic extracts from cultured cells were prepared under the conditions described above. Cells from xenograft tissues were prepared by resecting tumour tissue from severe combined immunodeficiency (SCID) mice (see the In vivo studies section), dissecting using sterile tools, placing on ice as quickly as possible to prevent degradation of protein by proteases, then snap freezing in liquid nitrogen and storing at -80°C until use. For Western blot analysis, 5 mg of tissue was homogenized in 300 µl of lysis buffer with an electric homogenizer for 2 h at 4°C. Homogenized samples were then centrifuged for 10 min at 14 000 g, at 4°C; the harvested cells were then washed with 10% phosphate buffered saline (PBS), pH 7.4 and lysed overnight at -20°C in lysis buffer (pH 8.0) containing 20 mM Tris (pH 7.5), 150 mM saline, 1 mM EDTA, 1 mM ethylene glycol tetra-acetic acid, 1% Triton™ X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerol phosphate, 1 mM trisodium vanadate, 1 µg/ml leupeptin and 1 mM phenylmethanesulphonylfluoride.
Cell debris was sedimented by centrifuging for 10 min at 14 000 g at 4°C and the supernatants were retained for analysis.
Protein concentrations of the supernatant from xenograft tissues and cytoplasmic extracts from cultured cells were determined using a protein detection assay kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer's instructions. Protein (50 µg) was solubilized at 100°C in Laemmli's sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (pH 8.8) containing 15% 2-mercaptoethanol. Each sample was separated using 10% SDS-PAGE at 150 V for 90 min. Separated polypeptides were then electrophoretically transferred to 0.2 mm nitrocellulose membranes (Schleicher & Schuell Bioscience, Keene, NH, USA) for 90 min at 100 V.
Membranes were blocked for 1 h at room temperature in Tris-buffered saline with 0.5% Tween (TBST; pH 7.6) containing 5% (w/v) nonfat dried milk. Blots were then probed overnight at 4°C with the following primary rabbit polyclonal antibodies: anti-NF-κB p65 (1:200 dilution), anti-MMP-9 (1:250 dilution), anti-IL-8 (1:200 dilution) and anti-β-actin (1:500 dilution) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Akt (1:200 dilution) and anti-pAkt (1:100 dilution) (both from Cell Signaling Technology ® , Danvers, MA, USA), and anti-CD31 (1:400 dilution) (clone MEC 13.3, BD Biosciences, San Jose, CA, USA). Blots were washed three times in 10% PBS and incubated with a secondary horseradish peroxidase-conjugated goat antirabbit immunoglobulin (Ig)G antibody (1:2000 dilution; Santa Cruz Biotechnology) for 40 min at room temperature. The blots were washed three times for 10 min each in distilled water and immunoreactivity was detected by enhanced chemiluminescence (ECL™; Amersham Biosciences, Piscataway, NJ, USA), according to the manufacturer's instructions.
DETECTION OF NF-kB DNA BINDING ACTIVITY
Nuclear protein extracts were prepared as J Li, F Li, H Wang et al. Effects of wortmannin in human breast cancer cells described previously, 18, 19 and were used to detect the level of NF-κB DNA binding activity by electrophoretic mobility shift analysis (EMSA). Briefly, a 22-bp oligonucleotide 5′-AGTTGAGGGACTTTCC CAGGC-3′ probe containing the NF-κB consensus sequence was labelled with 32 P-ATP (10 mCi/mmol) using T4 polynucleotide kinase. Then, 50 µM of labelled probe (10 000 counts/min) was added to 15 µg nuclear extract and incubated for 30 min at room temperature. For cold competition experiments, similar amounts of unlabelled NF-κB oligonucleotide or OCT1 oligonucleotide were used as nonspecific competitors. TATA binding protein (Abcam ® , Cambridge, MA, USA) was used as a nuclear loading control. After incubation with the various probes, nuclear protein extracts were separated on a 6% polyacrylamide gel for 90 min at 100 V in buffer containing 10% glycerol and 0.05% Nonidet P-40 solution. Gels were dried and directly exposed to a B-1 phosphor imaging screen and visualized with a GS-250 Molecular Imaging System (Bio-Rad).
DETECTION OF IL-8 AND MMP-9 PROTEIN
Levels of IL-8 and MMP-9 protein in the supernatants of cells cultured under the conditions described above were determined using a quantitative enzyme-linked immunosorbent assay kit (Calbiochem, Darmstadt, Germany), according to the manufacturer's instructions. The absorbance of the samples was compared with the standard curve.
CELL MOTILITY ASSAYS
Cell motility assays were performed using 8µm pore size Transwell Biocoat Control inserts (Becton Dickinson and Co., Franklin Lakes, NJ, USA) according to the manufacturer's instructions. MDA-MB-231 cells (1 × 10 6 ) from each of the wortmannin treatment groups were seeded into the chambers in Dulbecco's Modified Eagle Medium supplemented with 10% FBS and incubated at 37°C in 5% carbon dioxide. After 18 h incubation, cells on the top layer were removed by scrubbing and were fixed in 95% ethanol and stained with 0.1% crystal violet for 30 min. Using an optical microscope, the number of transmembrane cells was counted at five randomly selected high-power fields. Each field of view was checked to evaluate the invasion and metastasis of tumour cells in vitro, which were quantified and compared across treatment groups. Experiments were performed in duplicate and repeated four times.
CELL MIGRATION ASSAY
The migration of MDA-MB-231 cells was assessed by the modified Boyden chamber method. 20 The rate of migration was determined by quantifying the number of cells in six randomly selected fields. The extent of migration was expressed as the mean number of cells per microscope field.
ANGIOGENESIS ASSAY
Angiogenesis was determined by the chick embryo chorio-allantoic membrane assay. Fertilized white Leghorn chicken eggs, purchased from the Shanghai Institute of Health Sciences (Suzhou, China), were incubated at 37.8°C and 67% humidity. At day 3 of development, a window was cut into each eggshell and the underlying membrane, then resealed with an adhesive plaster. The eggs were incubated for a further 6 days, at which time the window was opened and the supernatant (1 µl) from wortmannin-treated (400 µM) MDA-MB-231 cells, or from wortmannin-treated (400 µM) J Li, F Li, H Wang et al.
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MDA-MB-231 cells that had been transfected for 48 h with the myr-Akt plasmid, was applied to the chorio-allantoic membrane; 1 µl of 10% PBS was used as a negative control. Eight eggs were included in each treatment group. At the same time (day 9), a Thermanox™ ring (Nunc™, Thermo Fisher Scientific, Rockford, IL, USA) was added to the chorio-allantoic membrane. The eggs were returned to the incubator for a further 4 days, after which they were opened and the chorio-allantoic membrane with the Thermanox™ ring was examined under a stereomicroscope, and photographed using a digital camera and flexible cold light (Olympus SZ51 and Olympus E410; Olympus, Tokyo, Japan). Blood vessels were counted inside the ring area (20 mm 2 ). The allantoic vascular plexus was subclassified into large vessels (diameter ≥ 50 µm) and microvessels (diameter < 50 µm).
IN VIVO STUDIES
For in vivo angiogenesis studies, 24 male SCID mice (6 weeks old, each weighing 18 -23 g) were purchased from the Shanghai Institute Animal Centre, Shanghai, China. Animals were housed under a 12-h light/12h dark cycle, with free access to food and water. The study protocol was reviewed and approved by the Ethics Committee on the Use of Animals in Experimentation at the Affiliated Hospital of Qingdao University Medical College, Qingdao University.
Each mouse received a subcutaneous injection, into the flank, of MDA-MB-231 cells (5 × 10 6 cells/mouse) in 200 µl of serum-free RPMI-1640 medium. When tumours were approximately 80 -120 mm 3 (at 4 months), a computer-generated randomization schedule was used to assign animals to receive intravenous wortmannin at doses of 1.0, 0.5 or 0.25 mg/kg or vehicle (20 mM PBS, pH 7.6, plus 5% dimethyl sulphoxide, pH 8.0), three times weekly for 3 weeks. At the end of the 3 weeks, resected tumours from the SCID mice were embedded in OCT1 oligonucleotide medium and quick frozen in liquid nitrogen. Frozen sections (4 µm) were prepared and postfixed with acetone. Sections were blocked in 20 mM PBS/5% FBS for 1 h, then incubated with a 1:400 dilution of anti-CD31 (clone MEC 13.3, BD Biosciences) overnight at 4°C; the CD31 signal (a specific marker of angiogenesis) was visualized by staining with streptavidin-biotin-peroxidase.
For in vivo invasion and metastasis studies, two groups of male SCID mice (n = 6 per group) were inoculated with MDA-MB-231 cells (1 × 10 6 cells per mouse in 50 µl RPMI-1640), by intraperitoneal (i.p.) injection. After 14 days, mice were treated with wortmannin (300 ng/g body weight; group 1) i.p. or 50 µl RPMI-1640 (group 2) three times weekly. Experiments were terminated at 21 days and animals were sacrificed by carbon dioxide inhalation. Autopsy was carried out for the macroscopic assessment of metastases; the numbers of seeded tumours in the abdominal cavity and liver were recorded.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® statistical software, version 10.0 (SPSS Inc. Chicago, IL, USA) for Windows ® . Data were presented as mean ± SD of three replicate experiments. Differences between groups were assessed by Student's t-test or analysis of variance. A P-value < 0.05 was considered to be statistically significant.
Results
AKT PHOSPHORYLATION IN VITRO
Treatment of MDA-MB-231 cells with wortmannin (0 -400 nM) suppressed Akt phosphorylation in a dose-dependent manner (Fig. 1A) . Inhibition of Akt J Li, F Li, H Wang et al.
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phosphorylation by wortmannin 400 nM was time dependent and was almost completely inhibited after 4 h (240 min) of treatment ( Fig. 1B) .
INVASIVENESS AND ANGIOGENESIS IN VITRO
Treatment with wortmannin inhibited the ability of MDA-MB-231 cells to invade the extracellular matrix, and the migration of MDA-MB-231 cells, in a dose-dependent manner. A significant reduction in invasion and migration was observed at wortmannin concentrations of 400 nM (P < 0.01 compared with untreated control).
Cell invasion and migration were partially restored in MDA-MB-231 cells that had been transfected with the myr-Akt plasmid, following treatment with 400 nM wortmannin for 4 h (P < 0.01 compared with 400 nM wortmannin-treated cells).
In vitro experiments showed that angiogenesis was significantly decreased by the application of supernatant from MDA-MB-231 cells treated with 400 nM wortmannin (P < 0.01 compared with negative control). Application of supernatant from MDA-MB-231 cells, transfected with the myr-Akt plasmid following treatment with 400 nM wortmannin for 4 h, resulted in restoration of angiogenesis, as demonstrated by an increase in the area covered by the Thermanox™ ring (P < 0.01 compared with 400 nM wortmannin-treated cells).
NF-kB DNA BINDING ACTIVITY AND NF-kB, MMP-9 AND IL-8 PROTEIN LEVELS
The DNA binding activity of NF-κB and the level of NF-κB protein were inhibited in a dose-dependent manner in MDA-MB-231 cells treated with wortmannin (0 -400 nM), as demonstrated by experiments involving EMSA and Western blot (Figs 2A, 2B) . Such experiments also showed dose-dependent decreases in MMP-9 and IL-8 protein in MDA-MB-231 cells following wortmannin treatment (Figs 2B, 2C; P < 0.01 compared with untreated controls). The reintroduction of Akt activity (by transfection of MDA-MB-231 cells with the myr-Akt plasmid) restored NF-κB DNA binding activity (P < 0.01 versus treatment with 400 nM wortmannin for 4 h), phosphorylation of Akt, and production of MMP-9 and IL-8 in cells treated with 400 nM wortmannin for 4 h (Figs 2A, 2C, 2D ).
ANGIOGENESIS IN VIVO
In SCID mice that developed orthotopic tumours following treatment with MDA-MB-231 cells, wortmannin administered three times daily for 3 weeks suppressed the production of phosphorylated Akt, NF-κB, (Fig. 3A) .
There was a significant reduction in the number of CD31-positive vessels in the tumours of wortmannin-treated mice (1.0 mg/kg) compared with the tumours of control animals that had not received wortmannin (P < 0.01; Fig. 3B ).
TUMOUR METASTASIS IN VIVO
Liver metastases occurred in all mice in the control group, but in only four out of six mice in the wortmannin-treated group (P < 0.01). Numerous off-white nodes were observed by macroscopic examination in the peritoneum, retina, mesentery, and intestinal and gastric walls of mice in the control group (data not shown). On autopsy, a significant reduction in the number of seeded tumour nodes was observed in the abdominal cavity organs of wortmannintreated mice compared with controls (mean ± SD 16.5 ± 1.26 versus 73.6 ± 11.4; P < 0.01).
Discussion
Increased activation and deregulation in the PI3K/Akt pathway have been implicated in 21 Akt is a well characterized serine/threonine kinase that is the central protein in the PI3K/Akt signalling pathway. Increases in the activity of Akt have been shown in many types of cancer, where it transmits a potent survival/ antiapoptotic signal. 22 Akt promotes cell survival through its effects on numerous downstream targets, including NF-κB, resulting in the transcription of antiapoptotic genes and genes implicated in metastatic and angiogenic processes. 23, 24 The present study aimed to determine the effects of wortmannin (a PI3K inhibitor) on Akt phosphorylation, NF-κB and NF-κBregulated gene products involved in invasion, metastasis and angiogenesis in a human breast cancer cell line, MDA-MB-231. Wortmannin was shown to inhibit the phosphorylation of Akt and block invasion, metastasis and angiogenesis of MDA-MB-231 cells in vitro and in vivo, in a dose-dependent manner. Furthermore, wortmannin was associated with suppression of NF-κB activity and reduction in levels of the NF-κBregulated gene products, MMP-9 and IL-8. That the activation of Akt was involved in these cellular and biochemical responses to wortmannin was verified by transfecting MDA-MB-231 cells with the myr-Akt plasmid, which encodes a constitutively active form of Akt. The reduced invasion, migration and angiogenesis of MDA-MB-231 cells and the suppression of NF-κB, MMP-9 and IL-8 observed in response to wortmannin were partially restored in cells transfected with the plasmid.
Viewed from a mechanistic perspective, wortmannin is able to interfere with the interplay between Akt and NF-κB-mediated signalling pathways, potentially leading to changes in the functional status of an array of effector molecules (such as E-cadherin and vascular endothelial growth factor) that regulate cell angiogenesis and metastasis. Although it is likely that the wortmannininduced reduction in invasion and angiogenesis by MDA-MB-231 cells was largely driven by the suppression of PI3K/Akt and the consequent switching off of the downstream proteins MMP-9 and IL-8 in the NF-κB signalling pathway, inhibition of other PI3K/Akt targets may also contribute to this altered metastatic phenotype.
Since angiogenesis contributes to the pathogenesis of breast cancer, the suppression of NF-κB signalling and MMP-9
and IL-8 levels by wortmannin is noteworthy, in light of the roles of these molecules in tumour metastasis and angiogenesis. 25 Taken together, the findings of the present study indicate that wortmannin inhibits metastasis and angiogenesis in human breast cancer cells, both in vitro and in vivo, through its action on PI3K/Akt/NF-κBmediated MMP-9 and IL-8 signalling pathways. Thus, Akt may represent a viable molecular target for breast cancer therapy.
